CYTK250117C28000
- 0.00
- 0.000.00%
Cytokinetics Newsroom
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $70 to $120
S&P 500 Futures Rise In Premarket Trading; Trump Media & Tech, Cytokinetics Lag
Truist Financial Reaffirms Their Buy Rating on Cytokinetics (CYTK)
Cytokinetics' Promising Future: Aficamten Approval and Robust Pipeline Drive Growth Prospects
Cautious Hold on Cytokinetics Amid Regulatory Uncertainties and Distant Milestones
Express News | Cytokinetics Inc - Pdufa Target Action Date for Aficamten Set for September 26, 2025
Express News | Cytokinetics Announces 2025 Corporate Milestones and Vision 2030
Cytokinetics Analyst Ratings
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BofA Securities Maintains Cytokinetics(CYTK.US) With Hold Rating, Maintains Target Price $62
Express News | Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Investors Push Cytokinetics (NASDAQ:CYTK) 3.7% Lower This Week, Company's Increasing Losses Might Be to Blame
S&P 500 Futures Drop In Premarket Trading; Sportradar Group, Cytokinetics Lead
Biggest Stock Movers Tuesday: X, CYTK, and More
Cytokinetics Says European Regulator Validated Its Application for Cardiomyopathy Drug Candidate
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating
Express News | Cytokinetics Inc - FDA Sets Pdufa Target Action Date for Aficamten Nda as Sept 26, 2025
Express News | Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Truist Financial Sticks to Their Buy Rating for Cytokinetics (CYTK)
Why Cytokinetics Stock Was a Nearly 5% Winner Today